BOLT BIOTHERAPEUTICS
NASDAQ: BOLT (Bolt Biotherapeutics, Inc.)
Last update: 14 hours ago6.59
0.23 (3.62%)
| Previous Close | 6.36 |
| Volume | 249,850 |
| Price / Sales | 2.37 |
| Price / Book | 0.970 |
| 52 Weeks Range |
| Operating Margin (TTM) | -991.41% |
| Diluted EPS (TTM) | -33.20 |
| Quarterly Revenue Growth (YOY) | -76.80% |
| Total Debt/Equity (MRQ) | 52.79% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | -57.90 M |
| Levered Free Cash Flow (TTM) | -34.68 M |
| Return on Assets (TTM) | -34.57% |
| Return on Equity (TTM) | -83.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Bolt Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 1.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -0.5 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.54 |
Select this tab to load the latest available analysis.
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.26% |
| % Held by Institutions | 46.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Board Of Trustees Of The Leland Stanford Junior University | 30 Jun 2026 | 35,977 |
| Pfizer Inc | 30 Jun 2026 | 31,305 |
| Lynx1 Capital Management Lp | 30 Jun 2026 | 30,800 |
| Nan Fung Group Holdings Ltd | 30 Jun 2026 | 5,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUJRATHI SHEILA | 6.27 | - | 85,821 | 538,098 |
| Aggregate Net Quantity | 85,821 | |||
| Aggregate Net Value ($) | 538,098 | |||
| Aggregate Avg. Buy ($) | 6.27 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GUJRATHI SHEILA | Officer | 23 Oct 2026 | Acquired (+) | 72,766 | 6.27 | 456,243 |
| GUJRATHI SHEILA | Officer | 23 Oct 2026 | Acquired (+) | 13,055 | 6.27 | 81,855 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |